Similar results have been reported in a study by Wedam et al., where bevacizumab was administered to locally advanced breast cancer patients (n = 21) and a significant inhibitory effect on tumor cell VEGFR2 expression (in both phosphorylation sites-Y951 and Y996) was demonstrated by IHC [26]. This evidence concerns the gene KDR and neoplasm.